Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Alpha Cognition (NASDAQ: ACOG) has successfully launched its product ZUNVEYL(R) (benzgalantamine) in the U.S. long-term care (LTC) market on March 17, 2025. The launch has shown positive early results with strong clinician and patient feedback, successful patient outcomes, and robust ordering momentum. The company secured Medicare reimbursement post-launch, enhancing patient access in LTC settings. Additionally, ACOG obtained a new composition of matter patent for the tablet formulation of benzgalantamine in the U.S.
Financial highlights include ZUNVEYL net product revenues of $0.35M and licensing revenue of $2.6M. Management confirmed that all launch objectives remain on track and within budget, with commercial execution proceeding according to plan.
Alpha Cognition (NASDAQ: ACOG) ha lanciato con successo il suo prodotto ZUNVEYL(R) (benzgalantamina) nel mercato statunitense dell'assistenza a lungo termine (LTC) il 17 marzo 2025. Il lancio ha mostrato risultati iniziali positivi con un riscontro favorevole da parte di clinici e pazienti, esiti terapeutici efficaci e un solido slancio negli ordini. L'azienda ha ottenuto il rimborso Medicare dopo il lancio, migliorando l'accesso dei pazienti nelle strutture LTC. Inoltre, ACOG ha acquisito un nuovo brevetto per la composizione della formulazione in compresse di benzgalantamina negli Stati Uniti.
I dati finanziari evidenziano ricavi netti da prodotto ZUNVEYL pari a 0,35 milioni di dollari e ricavi da licenze per 2,6 milioni di dollari. La direzione ha confermato che tutti gli obiettivi del lancio sono rispettati e rientrano nel budget, con l'esecuzione commerciale che procede secondo i piani.
Alpha Cognition (NASDAQ: ACOG) ha lanzado con 茅xito su producto ZUNVEYL(R) (benzgalantamina) en el mercado estadounidense de cuidados a largo plazo (LTC) el 17 de marzo de 2025. El lanzamiento ha mostrado resultados iniciales positivos con una fuerte retroalimentaci贸n de m茅dicos y pacientes, resultados exitosos para los pacientes y un s贸lido impulso en los pedidos. La empresa asegur贸 el reembolso de Medicare tras el lanzamiento, mejorando el acceso de los pacientes en entornos LTC. Adem谩s, ACOG obtuvo una nueva patente de composici贸n para la formulaci贸n en tabletas de benzgalantamina en Estados Unidos.
Los aspectos financieros incluyen ingresos netos por producto ZUNVEYL de 0,35 millones de d贸lares e ingresos por licencias de 2,6 millones de d贸lares. La direcci贸n confirm贸 que todos los objetivos del lanzamiento est谩n en camino y dentro del presupuesto, con la ejecuci贸n comercial avanzando seg煤n lo planeado.
Alpha Cognition (NASDAQ: ACOG)電� 2025雲� 3鞗� 17鞚� 氙戈淡 鞛リ赴 鞖旍枒(LTC) 鞁滌灔鞐� 鞛愳偓 鞝滍拡 ZUNVEYL(R) (氩れ臧堧瀫韮�氙�)鞚� 靹标车鞝侅溂搿� 於滌嫓頄堨姷雼堧嫟. 鞚措矆 於滌嫓電� 鞛勳儊 鞚橃偓鞕� 頇橃瀽霌れ潣 旮嶌爼鞝侅澑 頂茧摐氚�, 靹标车鞝侅澑 頇橃瀽 瓴瓣臣, 攴鸽Μ瓿� 瓴碃頃� 欤茧 歃濌皜靹鸽ゼ 氤挫澊氅� 齑堦赴 膦嬱潃 靹标臣毳� 雮橅儉雰堨姷雼堧嫟. 須岇偓電� 於滌嫓 頉� 氅旊敂旒�鞏� 靸來櫂鞚� 頇曤炒頃橃棳 LTC 頇橁步鞐愳劀 頇橃瀽 鞝戧芳靹膘潉 頄レ儊鞁滌及鞀惦媹雼�. 霕愴暅 ACOG電� 氙戈淡鞐愳劀 氩れ臧堧瀫韮�氙� 鞝曥牅 鞝滍槙鞐� 雽�頃� 靸堧鞖� 臁办劚氍� 韸鬼棃毳� 旆摑頄堨姷雼堧嫟.
鞛 頃橃澊霛检澊韸鸽電� ZUNVEYL 靾滌牅頀� 毵れ稖 35毵� 雼煬 氚� 霛检澊靹犾姢 靾橃澋 260毵� 雼煬臧� 韽暔霅╇媹雼�. 瓴届榿歆勳潃 氇摖 於滌嫓 氇╉憸臧� 瓿勴殟雽�搿� 鞓堨偘 雮挫棎靹� 靾滌“搿矊 歆勴枆霅橁碃 鞛堨潓鞚� 頇曥澑頄堨姷雼堧嫟.
Alpha Cognition (NASDAQ : ACOG) a lanc茅 avec succ猫s son produit ZUNVEYL(R) (benzgalantamine) sur le march茅 am茅ricain des soins de longue dur茅e (LTC) le 17 mars 2025. Ce lancement a donn茅 des r茅sultats positifs pr茅coces avec un retour favorable des cliniciens et des patients, des r茅sultats patients r茅ussis et un fort dynamisme des commandes. L'entreprise a obtenu le remboursement Medicare apr猫s le lancement, am茅liorant l'acc猫s des patients dans les 茅tablissements LTC. De plus, ACOG a obtenu un nouveau brevet de composition pour la formulation en comprim茅s de benzgalantamine aux 脡tats-Unis.
Les points financiers cl茅s incluent des revenus nets produits ZUNVEYL de 0,35 M$ et des revenus de licences de 2,6 M$. La direction a confirm茅 que tous les objectifs du lancement restent sur la bonne voie et dans le budget, avec une ex茅cution commerciale conforme au plan.
Alpha Cognition (NASDAQ: ACOG) hat sein Produkt ZUNVEYL(R) (Benzgalantamin) am 17. M盲rz 2025 erfolgreich auf dem US-amerikanischen Markt f眉r Langzeitpflege (LTC) eingef眉hrt. Der Produktstart zeigte positive erste Ergebnisse mit starkem Feedback von Klinikern und Patienten, erfolgreichen Behandlungsergebnissen und robustem Bestellwachstum. Das Unternehmen sicherte sich nach dem Start die Medicare-Erstattung, was den Zugang der Patienten in LTC-Einrichtungen verbessert. Zudem erhielt ACOG ein neues Patent f眉r die Zusammensetzung der Tablettenformulierung von Benzgalantamin in den USA.
Finanzielle Highlights umfassen ZUNVEYL Nettoprodukterl枚se von 0,35 Mio. USD und Lizenzums盲tze von 2,6 Mio. USD. Das Management best盲tigte, dass alle Ziele des Produktstarts im Zeitplan und im Budget liegen und die kommerzielle Umsetzung planm盲脽ig verl盲uft.
- Successful launch of ZUNVEYL in U.S. long-term care market
- Secured Medicare reimbursement, improving market access
- Obtained new composition of matter patent for tablet formulation
- Generated $0.35M in product revenue and $2.6M in licensing revenue
- Strong initial ordering momentum and positive clinical feedback
- Initial product revenue of $0.35M indicates early-stage commercialization with limited market penetration
Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget. Early clinician and patient feedback has been positive, citing successful initial patient outcomes and strong ordering momentum, with rapid product replenishment by wholesalers. The field team reported broad engagement across high-priority LTC accounts nationwide. Importantly, Medicare reimbursement was secured soon after launch, significantly improving access for patients in LTC settings. Management reiterated that all launch objectives remain on track and within budget, with commercial execution progressing as planned.
To view the full announcement, including downloadable images, bios, and more, .
Key Takeaways:
Officially launched ZUNVEYL to US market in March, 2025.
The Company secured a new composition of matter patent in the U.S., covering the tablet formulation of benzgalantamine.
ZUNVEYL net product revenues of
$0.35M ; with licensing revenue of$2.6M .
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
[email protected]
Source:
To view the source version of this press release, please visit
FAQ
What is the revenue generated by ACOG's ZUNVEYL in Q1 2025?
When did Alpha Cognition launch ZUNVEYL in the US market?
What recent patent did Alpha Cognition (ACOG) secure for ZUNVEYL?
Has ZUNVEYL received Medicare reimbursement approval?
How has the market responded to ZUNVEYL's launch by Alpha Cognition?
